进展期乳腺癌术后多西他赛联合卡培他滨化疗同步放疗的临床研究
|
摘要
目的探讨进展期乳腺癌术后多西他赛联合卡培他滨化疗同步放疗的临床效果。方法将本院2011年1月至2015年1月收治的进展期乳腺癌术后患者82例随机分为观察组与对照组,每组各41例。观察组患者采用多西他赛联合卡培他滨化疗同步放疗,对照组患者仅采用化疗治疗。比较两组患者近期疗效、随访1年和2年后生存和复发情况及不良反应发生情况。结果观察组患者治疗总有效率显著高于对照组(P<0.05)。随访1年,两组患者生存率比较无显著差异(P>0.05);随访2年,观察组患者生存率高于对照组(P<0.05)。随访1年和2年,观察组患者复发率均显著低于对照组(P<0.05)。两组患者胃肠道反应、骨髓抑制、肝功能异常及白细胞减少不良反应发生率比较均无显著差异(P>0.05)。结论进展期乳腺癌术后多西他赛联合卡培他滨化疗同步放疗可延长患者生存时间,降低复发率,近期疗效显著,具有重要的研究意义。
Objective To explore the clinical effect of docetaxel combined with capecitabine chemotherapy in patients with advanced breast cancer after concurrent radiotherapy. Method 82 cases of advanced breast cancer patients admitted to our hospital from January 2011 to January 2015 were randomly divided into observation group and control group, 41 cases in each group. Observation group patients were treated by docetaxel combined with capecitabine chemotherapy concurrent with radiotherapy, while control group patients only received chemotherapy treatment. Compared the short-term efficacy, follow-up of 1 year and 2 years of survival and recurrence, and adverse reactions occurred between the two groups. Result The total effective rate of observation group was significantly higher than that of control group(P < 0.05). After 1 year of follow-up, there was no significant difference in survival rate between the two groups(P > 0.05). After 2 years of follow-up, the survival rate of observation group was higher than that of control group(P < 0.05). Followed up for 1 year and 2 years, the recurrence rate of observation group were significantly lower than that of control group(P < 0.05). There were no significant differences in the incidence of gastrointestinal reactions, bone marrow suppression, abnormal liver function and reduction of white blood cells in the two groups(P > 0.05). Conclusion The short-term efficacy of docetaxel combined with capecitabine chemotherapy concurrent with radiotherapy in patients with advanced breast cancer is significant, which can prolong the survival time and reduce the recurrence rate.
Objective To explore the clinical effect of docetaxel combined with capecitabine chemotherapy in patients with advanced breast cancer after concurrent radiotherapy. Method 82 cases of advanced breast cancer patients admitted to our hospital from January 2011 to January 2015 were randomly divided into observation group and control group, 41 cases in each group. Observation group patients were treated by docetaxel combined with capecitabine chemotherapy concurrent with radiotherapy, while control group patients only received chemotherapy treatment. Compared the short-term efficacy, follow-up of 1 year and 2 years of survival and recurrence, and adverse reactions occurred between the two groups. Result The total effective rate of observation group was significantly higher than that of control group(P < 0.05). After 1 year of follow-up, there was no significant difference in survival rate between the two groups(P > 0.05). After 2 years of follow-up, the survival rate of observation group was higher than that of control group(P < 0.05). Followed up for 1 year and 2 years, the recurrence rate of observation group were significantly lower than that of control group(P < 0.05). There were no significant differences in the incidence of gastrointestinal reactions, bone marrow suppression, abnormal liver function and reduction of white blood cells in the two groups(P > 0.05). Conclusion The short-term efficacy of docetaxel combined with capecitabine chemotherapy concurrent with radiotherapy in patients with advanced breast cancer is significant, which can prolong the survival time and reduce the recurrence rate.
引文
[1]马磊,伍思培,邓旭斌,等.D-CIK治疗抑制进展期乳腺癌中循环肿瘤细胞的初步研究[J].海南医学,2014,6(13):1884-1887.
[2]Yardley DA.Adverse event management of m TOR inhibitors during treatment of hormone receptor-positive advanced breast cancer:considerations for oncologists[J].Clin Breast Cancer,2014,14(5):297-308.
[3]孙燕.内科肿瘤学[M].北京:人民卫生出版社,2006:995.
[4]郝静,赵鹏飞.多西他赛与阿霉素和环磷酰胺新辅助治疗局部晚期乳腺癌的临床研究[J].中国临床药理学杂志,2014,11(4):303-305.
[5]邱小兰.新辅助化疗在局部进展期乳腺癌保乳治疗中的临床意义分析[J].湖南中医药大学学报,2016,14(2):975-975.
[6]王绪麟,刘新梅,徐静,等.局部进展期乳腺癌新辅助化疗后保乳治疗的疗效观察[J].中国普通外科杂志,2013,22(8):1099-1102.
[7]李金平,李宏,曾涛,等.进展期乳腺癌新辅助化疗后保乳手术的临床研究[J].海南医学,2013,24(10):1435-1437.
[8]温凤云,马特,于洪,等.局部进展期乳腺癌新辅助化疗后的保乳治疗[J].山东医药,2012,52(24):83-85.
[9]刘庆仪,黄小云,李少英,等.新辅助化疗治疗局部进展期乳腺癌的临床观察[J].中国癌症防治杂志,2010,2(2):85-88.
[10]宋震宇.新辅助化疗对局部进展期乳腺癌保乳治疗的效果观察[J].中国实用医药,2016,21(5):154-155.
[11]赵晚君,梅振宇,盛勇.乳腺癌新辅助化疗的研究进展[J].中国肿瘤外科杂志,2016,8(4):270-272.
[12]董玉亭.吉西他滨联合顺铂或卡培他滨治疗晚期乳腺癌的疗效比较[J].国际肿瘤学杂志,2010,37(12):949-950.
[13]郝代钧,樊建淑,张海燕.吉西他滨联合卡培他滨二线治疗晚期乳腺癌[J].中国癌症杂志,2007,17(8):647-649.
[14]汪颖,贾卫娟,饶南燕,等.含卡培他滨方案一线或后线治疗晚期乳腺癌的疗效比较[J].中华肿瘤防治杂志,2016,23(15):1006-1010.
[15]徐正阳,袁祖国,周涛琪,等.长春瑞滨联合卡培他滨治疗晚期乳腺癌疗效观察[J].温州医科大学学报,2014,44(6):441-444.
[16]高会全,马学真,朱超,等.卡培他滨治疗进展期三阴性乳腺癌疗效分析[J].肿瘤防治研究,2014,41(4):383-386.
[17]王妍彦.卡培他滨联合扶正消瘤方治疗进展期乳腺癌疗效观察[J].现代中西医结合杂志,2016,25(3):306-308.
[18]周桂霞,戴相昆,徐寿平,等.乳腺癌术后放疗3种治疗计划的剂量学研究[J].中华放射医学与防护杂志,2010,30(3):314-316.
[19]包虹.33例Ⅰ期乳腺癌保乳术后不同放射治疗方式的剂量学研究[J].中国医学物理学杂志,2011,28(4):2725-2728.
[20]艾秀清,木克代斯·拜克提亚尔,韩有溪,等.乳腺癌根治术后三维调强放疗与三维适形放疗剂量学比较及不良反应观察[J].临床和实验医学杂志,2014,13(5):365-368.
[2]Yardley DA.Adverse event management of m TOR inhibitors during treatment of hormone receptor-positive advanced breast cancer:considerations for oncologists[J].Clin Breast Cancer,2014,14(5):297-308.
[3]孙燕.内科肿瘤学[M].北京:人民卫生出版社,2006:995.
[4]郝静,赵鹏飞.多西他赛与阿霉素和环磷酰胺新辅助治疗局部晚期乳腺癌的临床研究[J].中国临床药理学杂志,2014,11(4):303-305.
[5]邱小兰.新辅助化疗在局部进展期乳腺癌保乳治疗中的临床意义分析[J].湖南中医药大学学报,2016,14(2):975-975.
[6]王绪麟,刘新梅,徐静,等.局部进展期乳腺癌新辅助化疗后保乳治疗的疗效观察[J].中国普通外科杂志,2013,22(8):1099-1102.
[7]李金平,李宏,曾涛,等.进展期乳腺癌新辅助化疗后保乳手术的临床研究[J].海南医学,2013,24(10):1435-1437.
[8]温凤云,马特,于洪,等.局部进展期乳腺癌新辅助化疗后的保乳治疗[J].山东医药,2012,52(24):83-85.
[9]刘庆仪,黄小云,李少英,等.新辅助化疗治疗局部进展期乳腺癌的临床观察[J].中国癌症防治杂志,2010,2(2):85-88.
[10]宋震宇.新辅助化疗对局部进展期乳腺癌保乳治疗的效果观察[J].中国实用医药,2016,21(5):154-155.
[11]赵晚君,梅振宇,盛勇.乳腺癌新辅助化疗的研究进展[J].中国肿瘤外科杂志,2016,8(4):270-272.
[12]董玉亭.吉西他滨联合顺铂或卡培他滨治疗晚期乳腺癌的疗效比较[J].国际肿瘤学杂志,2010,37(12):949-950.
[13]郝代钧,樊建淑,张海燕.吉西他滨联合卡培他滨二线治疗晚期乳腺癌[J].中国癌症杂志,2007,17(8):647-649.
[14]汪颖,贾卫娟,饶南燕,等.含卡培他滨方案一线或后线治疗晚期乳腺癌的疗效比较[J].中华肿瘤防治杂志,2016,23(15):1006-1010.
[15]徐正阳,袁祖国,周涛琪,等.长春瑞滨联合卡培他滨治疗晚期乳腺癌疗效观察[J].温州医科大学学报,2014,44(6):441-444.
[16]高会全,马学真,朱超,等.卡培他滨治疗进展期三阴性乳腺癌疗效分析[J].肿瘤防治研究,2014,41(4):383-386.
[17]王妍彦.卡培他滨联合扶正消瘤方治疗进展期乳腺癌疗效观察[J].现代中西医结合杂志,2016,25(3):306-308.
[18]周桂霞,戴相昆,徐寿平,等.乳腺癌术后放疗3种治疗计划的剂量学研究[J].中华放射医学与防护杂志,2010,30(3):314-316.
[19]包虹.33例Ⅰ期乳腺癌保乳术后不同放射治疗方式的剂量学研究[J].中国医学物理学杂志,2011,28(4):2725-2728.
[20]艾秀清,木克代斯·拜克提亚尔,韩有溪,等.乳腺癌根治术后三维调强放疗与三维适形放疗剂量学比较及不良反应观察[J].临床和实验医学杂志,2014,13(5):365-368.